Malaysian Genomics partners De Cell to bring cell-gene therapy programme to market

Malaysian Genomics Resource Centre Bhd executive chairman Azri Azerai

KUALA LUMPUR: Malaysian Genomics Resource Centre Bhd's (MGRC) wholly-owned subsidiary MGRC Healthcare Sdn Bhd is collaborating with De Cell Bhd for the commercialisation of the former's cell-gene therapy programme.

In a statement, the genomics and biopharmaceutical specialist said it will provide technical and production support to optimise the operational efficiency and market deployment of the EXOGENETIX programme.

De Cell will take on the role of exclusive marketing partner, overseeing all promotional and trademark activities to amplify the programme's market presence and success.

"This collaboration underscores MGRC’s commitment to spearheading innovation and transforming healthcare outcomes through advanced biotechnologies.

"By combining MGRC Healthcare's production capabilities with De Cell's marketing acumen, this partnership is poised to significantly advance the reach and effectiveness of the EXOGENETIX programme," said Malaysian Genomics executive chairman Azri Azerai.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Next In Business News

Oil gains 1% on hopes of firmer demand
JPMorgan investors weigh CEO Dimon’s strategy, succession plan
Muhibbah rides on Cambodian tourism uptick
Feytech gears up for expansion to meet growing demand
Ready to rise up the ranks again
SC working overtime to combat spread of scams
Russia and Malaysia sign tax agreement
GDP up 4.2% in 1Q24
Chinese firms invest in ‘green’ jet fuel

Others Also Read